Abstract:Sample hemolysis is conventionally defined as the presence of a variable amount of cell-free hemoglobin in serum or plasma. The reference (i.e. “normal”) concentration of free and measurable hemoglobin conventionally ranges between 0.22 and 0.25 g/L in serum and between 0.10 and 0.13 g/L in plasma, respectively [1]. Although no definitive evidence exists about the threshold of “pathological” hemolysis in blood samples, universal consensus has been reached that clinically significant interference for the most hemolysis-vulnerable tests (i.e. potassium, lactate dehydrogenase, aspartate aminotransferase) may start with concentrations of cell-free hemoglobin ≥0.5 g/L [2, 3]. Notably, this cut-off is also conventionally used for monitoring phlebotomy practice [4]. Although the very first studies about the impact of sample hemolysis on the quality of laboratory testing have been published more than 40 years ago [5], the frequency of hemolyzed samples remains high and generates remarkable challenges in clinical laboratory practice [6–8]. The first important issue is distinguishing between in vitro (i.e. spurious) and in vivo (i.e. hemolytic anemia) hemolysis. The differentiation between these conditions is not meaningless because the former case reflects a kaleidoscope of problems emerging throughout preanalytical sample management, thus including blood drawing, handling, transportation, storage and preparation for testing, whilst the latter mirrors a life-threatening condition, which must be timely communicated to the clinicians for adopting the most appropriate care options. According to this perspective, the second and almost consequential aspect is the need of systematically monitoring sample quality for accurate and rapid identification of hemolysis in serum or plasma, as also currently endorsed by many international accreditation standards such as the International Standards Organization (ISO) 15189:2012 and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) [9]. The most obvious consequence is that all laboratories should adopt a reliable strategy for systematic monitoring of sample quality and, moreover, for identifying the presence of, and quantifying, cell-free hemoglobin in either serum or plasma. In this issue of the journal, we publish an interesting study aimed to assess whether visual inspection of sample hemolysis by comparison with a color chart, rather than automatic assessment of serum or plasma indices, may have an impact on patient safety [10]. Interestingly, the authors concluded that nearly one-third of test results generated with manual handling of hemolyzed specimens were incorrectly managed, mainly for incorrect release of hemolysis-sensitive tests results or for unnecessary suppression of data in specimens with non-clinically significant degrees of hemolysis. In both cases, these circumstances may seriously jeopardize the managed care because release of data biased for the presence of hemolysis may then trigger inappropriate therapeutic options (i.e. administration of potassium-lowering therapy in patients with “spurious” hyperkalemia), whereas unjustified test suppression may delay both diagnosis and treatment of potentially fatal diseases (i.e. delayed or inappropriate management of arrhythmias due to underdiagnosis of in vivo hyperkalemia). Color vision is conventionally defined as the capability of distinguishing colors according to the wavelengths of light reflected, emitted or transmitted. The individual ability to identify colors and perceiving their intensity depends on multiple factors, such as the local environment and its relative light exposure, but may also relay on some genetic (i.e. Opsin gene polymorphisms), anatomic and pathological aspects, which ultimately make the eyes of one subject more capable than others (color blindness, also known as “daltonism”, is a paradigmatic example) (Figure 1) [11, 12]. All these factors make color recognition rather heterogeneous in different environments and among different individuals, thus supporting the hypothesis that visual assessment of sample quality may be highly inaccurate. Previous and highly reliable evidence has been provided that visual detection of hemolyzed samples is more inaccurate compared with automatic detection [13, 14], thus paving the way to adopting more precise and standardized approaches. The current generation of preanalytical platforms and

Quality Standards for Sample Processing, Transportation, and Storage in Hemostasis Testing

Preanalytical Issues in Hemostasis and Thrombosis Testing

Quality Standards for Sample Collection in Coagulation Testing

Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories

Post-analytical Issues in Hemostasis and Thrombosis Testing

Stability of Hemostasis Parameters in Whole Blood, Plasma, and Frozen Plasma: Literature Review and Recommendations of the SFTH (French Society of Thrombosis and Haemostasis)

Preanalytical Variables in Coagulation Testing: Setting the Stage for Accurate Results

Collection of Coagulation Specimens

Pre-Analytical Sample Quality: Metabolite Ratios as an Intrinsic Marker for Prolonged Room Temperature Exposure of Serum Samples

Influencing Factors of Blood Sample Quality Before Laboratory Tests

International Council for Standardisation in Haematology (ICSH) recommendations for collection of blood samples for coagulation testing

Preanalytical quality improvement: in quality we trust

Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature

Effects of blood sample storage time, temperature, anti-coagulants and blood stabiliser on lymphocyte phenotyping

Causes, consequences and management of sample hemolysis in the clinical laboratory

Inadvertent omission of a specimen integrity comment – an overlooked post-analytical error

Visual assessment of sample quality: quo usque tandem?

A-150 Extended Pre-Analytical Stability Validation for Coagulation Tests in Brazilian Clinical Laboratory

Pre-processing stability of routine clinical chemistry analytes in a clotting tube; investigating the (un)suitability for at-home sample collection

The stability of 65 biochemistry analytes in plasma, serum, and whole blood

Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia